Search results for: “astrazeneca”
-
AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States
•
LONDON: AstraZeneca today announced $3.5 billion of capital investment in the United States focused on expanding the Company’s…
-
AstraZeneca to deliver $80 billion revenue by 2030
•
LONDON: AstraZeneca revealed its bold ambition to deliver $80 billion in Total Revenue by 2030, up from $45.8…
-
AstraZeneca announces $1.5 billion investment in Singapore manufacturing
•
LONDON: AstraZeneca has unveiled plans to construct a state-of-the-art manufacturing facility in Singapore, dedicated to the production of…
-
AstraZeneca bolsters stake in Cellectis with $140 million investment
•
AstraZeneca has completed a $140 million equity investment in Cellectis, a biotech firm at the forefront of gene-editing…
-
EU Panel endorses AstraZeneca’s breast cancer drug Truqap
•
LONDON: The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of…
-
AstraZeneca reports 19% increase in Q1 2024 revenue to $12.67 billion
•
LONDON: AstraZeneca has kicked off the year with a remarkable 19% increase in Total Revenue, reaching $12.679 billion…
-
Angle plc signs new commercial agreement with AstraZeneca
•
LONDON: ANGLE plc (AIM:AGL), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use…
-
AstraZeneca to acquire Fusion Pharmaceuticals in a $ 2.0 billion deal
•
LONDON: AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing…
-
AstraZeneca enters definitive agreement to acquire Amolyt Pharma for $1.05 billion
•
AstraZeneca announced that it has entered into a definitive agreement to acquire Amolyt Pharma, a clinical-stage biotechnology company focused…
-
AstraZeneca reports strong growth in 2023 despite COVID-19 challenges
•
AstraZeneca, a global biopharmaceutical company, announced its financial results for the full year 2023, showing a 6% increase…
-
AstraZeneca to buy Gracell Biotechnologies for up to $1.2bn to boost cell therapy pipeline
•
Acquisition of Gracell completed AstraZeneca has agreed to acquire Gracell Biotechnologies, a company developing cell therapies for cancer…
-
AstraZeneca signs deal to acquire Icosavax Inc. for $1.1 billion
•
LONDON, UK: AstraZeneca has entered into a definitive agreement to acquire Icosavax Inc. (NASDAQ: ICVX), a US-based clinical-stage…
Stay Informed with the Latest News and Updates
- Contact Us
- London Stock Exchange
- Singapore Exchange
- Canadian Exchange
- Australian Exchange
- Oslo Bourse
- PSX
- Ratings
- Euronext
- MENA
- Nasdaq Nordic
- Wire
- Business & Finance
- Gadget Reviews
- About Us: A Comprehensive Financial News Database
All news and articles on NewsnReleases are based on press releases, corporate announcements and analysts’ reports issued to London Stock Exchange (LSE), Euronext, Singapore Exchange (SGX), Japan Stock Exchange (JPX), Dubai Financial Market (DFM), Saudi Stock Exchange (Tadawul), Qatar Stock Exchange (QSE), BSEIndia, Australia Stock Exchange etc.